Kichenadasse G, et al. - A pooled analysis of individual patient-level data from four international, multicenter clinical trials was done in order to investigate whether BMI was correlated with survival outcomes and adverse events in people with non–small cell lung cancer (NSCLC) treated with atezolizumab. A total of 2,110 individuals from a total pool of 2,261 across four trials were enrolled. In people with NSCLC, high BMI seemed to be independently related to enhanced survival with atezolizumab, increasing the likelihood that baseline BMI should be acknowledged as a stratification factor in future immune checkpoint inhibitor therapy trials.